Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Mar 16;97(6):419-24.
doi: 10.1093/jnci/dji067.

Risk of cardiac death after adjuvant radiotherapy for breast cancer

Affiliations
Meta-Analysis

Risk of cardiac death after adjuvant radiotherapy for breast cancer

Sharon H Giordano et al. J Natl Cancer Inst. .

Abstract

Background: Women with breast cancer who are treated with adjuvant radiation have a decreased risk of local recurrence but an increased risk of mortality from ischemic heart disease. Patients with left-sided breast tumors receive a higher dose of radiation to the heart than patients with right-sided tumors. Because radiation techniques have improved over time, we investigated whether the risk of death from ischemic heart disease after adjuvant breast radiotherapy decreased over time.

Methods: We used the 12-registry 1973-2000 dataset from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Women (n = 27,283) treated with adjuvant radiation for breast cancer diagnosed in 1973-1989 were included in the study. Ischemic heart disease mortality was calculated at 15 years and compared for women diagnosed during 1973-1979, 1980-1984, and 1985-1989. Cox proportional hazards models were used to calculate the hazard of death from ischemic heart disease for women diagnosed 1973-1988 and censored at 12 years. All statistical tests were two-sided.

Results: There were no differences in age, race/ethnicity, disease stage, or follow-up time between the 13 998 women with left-sided and 13 285 with right-sided cancer. For women diagnosed in 1973-1979, there was a statistically significant difference in 15-year mortality from ischemic heart disease between patients with left-sided (13.1%, 95% confidence interval [CI] = 11.6 to 14.6) and those with right-sided (10.2%, 95% CI = 8.9 to 11.5) breast cancer (P = .02); no such difference was found for women diagnosed in 1980-1984 (9.4%, [95% CI = 8.1 to 10.6] versus 8.7% [95% CI = 7.4 to 10.0], respectively, P = .64) or 1985-1989 (5.8% [95% CI = 4.8 to 6.8] versus 5.2% [95% CI = 4.4 to 5.9], respectively, P = .98). In the Cox model, the hazard ratio [HR] for ischemic heart disease mortality for women with left-sided versus women with right-sided disease was 1.50 (95% CI = 1.19 to 1.87) in 1979. With each succeeding year after 1979, the hazard of death from ischemic heart disease for women with left-sided versus those with right-sided disease declined by 6% (HR = 0.94, 95% CI = 0.91 to 0.98).

Conclusions: Risk of death from ischemic heart disease associated with radiation for breast cancer has substantially decreased over time.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival curves by breast cancer laterality and year of diagnosis. Mean time of follow-up was 96 months, 113 months, and 121 months for patients diagnosed in 1973–1979, 1980–1984, and 1985–1989, respectively. Broken lines = patients with right-sided breast cancer; solid lines = patients with left-sided breast cancer; blue lines = 1973–1979 cohort; red lines = 1980–1984 cohort; green lines = 1985–1989.
Fig. 2
Fig. 2
Kaplan–Meier survival curves by breast cancer laterality and year of diagnosis for patients with in situ and localized stage tumors. Mean time of follow-up was 121 months, 133 months, and 132 months for patients diagnosed in 1973–1979, 1980–1984, and 1985–1989, respectively. Broken lines = patients with right-sided breast cancer; solid lines = patients with left-sided breast cancer; blue lines = 1973–1979 cohort; red lines = 1980–1984 cohort; green lines = 1985–1989.
Fig. 3
Fig. 3
Kaplan – Meier survival curves by breast cancer laterality and year of diagnosis for patients with regional-stage tumors. Mean time of follow-up was 88 months, 94 months, and 101 months for patients diagnosed in 1973– 1979, 1980 – 1984, and 1985 – 1989, respectively. Broken lines = patients with right-sided breast cancer; solid lines = patients with left-sided breast cancer; blue lines = 1973–1979 cohort; red lines = 1980–1984 cohort; green lines = 1985–1989.

Comment in

  • Radiotherapy for breast cancer.
    Cuzick J. Cuzick J. J Natl Cancer Inst. 2005 Mar 16;97(6):406-7. doi: 10.1093/jnci/dji086. J Natl Cancer Inst. 2005. PMID: 15769997 No abstract available.

References

    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 12 Regs Public-Use, Nov 2002 Sub (1973–2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission. [CD-Rom]
    1. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456–61. - PubMed
    1. Anonymous Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group [see comment] Lancet. 2000;355:1757–70. - PubMed
    1. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b. Trial N Engl J Med. 1997;337:949–55. - PubMed
    1. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8. - PubMed

Publication types

MeSH terms